A phosphorylation-deficient Bcl2 T69A mutant sensitizes GBM cells to oxidative stress-induced apoptosis, suggesting the HSP90-PKM2-Bcl2 axis as a potential therapeutic target in GBM intervention [116]. This evidence concerns the gene BCL2 and glioblastoma.